Company Description
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Rα for the treatment of Type 2 allergic diseases.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 261 |
| CEO | Michael Henderson |
Contact Details
Address: Building 17, Suite 102b Waltham, Massachusetts 02453 United States | |
| Phone | 650 394 5230 |
| Website | apogeetherapeutics.com |
Stock Details
| Ticker Symbol | APGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1974640 |
| CUSIP Number | 03770N101 |
| ISIN Number | US03770N1019 |
| Employer ID | 93-4958665 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jane Pritchett V. Henderson | Chief Financial Officer |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Noel Kurdi | Vice President of Investor Relations |
| Matthew Batters J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs and Toxicology |
| Monica Forbes | Senior Vice President of Finance |
| Dr. Mehrak Kiankarimi Ph.D. | Senior Vice President of Program and Portfolio |
| Dan Mulreany | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 2, 2026 | PREM14A | Filing |
| Jul 1, 2026 | 144 | Filing |
| Jun 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 23, 2026 | SCHEDULE 13D/A | Filing |
| Jun 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 22, 2026 | 144 | Filing |
| Jun 22, 2026 | 144 | Filing |